Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor

NCT01603212 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Vemurafenib
DRUG: IL-2
DRUG: Interferon Alpha-2b

Sponsor

M.D. Anderson Cancer Center